Pharmacology Update: Tapentadol for Neuropathic Pain

American Journal of Hospice and Palliative Medicine

Volumn 29, Issue 8, 2012, Pages 663-666

  Pierce, Deidre M ^a   Shipstone, Emmanuel ^a  

^a EAST TENNESSEE STATE UNIVERSITY   (United States)

Author keywords

chronic pain; neuropathic pain; opioids; palliative medicine; symptom assessment; symptoms

Indexed keywords

ANALGESIC AGENT; MU OPIATE RECEPTOR; PHENOL DERIVATIVE; TAPENTADOL;

ARTICLE; DELAYED RELEASE FORMULATION; DRUG ANTAGONISM; HUMAN; NEURALGIA;

ANALGESICS; DELAYED-ACTION PREPARATIONS; HUMANS; NEURALGIA; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 84869078936     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909111434634     Document Type: Article

References (19)

1. Dworkin RH,O'Connor AB,Backonja M, et al.Pharmacologic management of neuropathic pain: evidence-based recommendations.Inter Assoc Study Pain. 2007;132 (3): 237-251.
2. Galluzzi KE.Managing neuropathic pain.J Am Osteopath Assoc. 2007;107 (suppl 6): ES39-ES48.
3. Serpell MG,Makin A,Harvey A.Acute pain physiology and pharmacological targets: the present and future.Acute Pain. 1998;1 (3): 31-47.
4. Scadding S.Neuropathic pain: pain in neurological disease.ACNR. 2003;3 (2): 8-14.
5. Rogers M,Moradimehr A,Rasheed A,Baumrucker SJ.Memantine (Namenda) for neuropathic pain.Am J Hosp Palliat Med. 2009;26 (1): 57-59.
6. McMakin C.Non-pharmacologic treatment of neuropathic pain using frequency specific microcurrent.Pain Practitioner. 2010;20 (3): 68-73.
7. Gilron I,Watson PN,Cahill CM,Moulin DE.Neuropathic pain: a practical guide for the clinician.CMAJ. 2006;175 (3): 265-275.
8. Moosa RS,McFayden M L,Miller R,Rubin J.Carbamezapine and its metabolites in neuralgias: concentration-effect relations.Euro J Clin Pharmacol. 1993;45 (4): 297-301.
9. Hartrick CT,Rozek RJ.Tapentadol in pain management.CNS Drugs. 2011;25 (5): 359-370.
10. Wade WE,Spruill WJ.Tapentadol hydrochloride: a centrally acting oral analgesic.Clin Ther. 2009;31 (12): 2804-2818.
11. Walter W,Howard F,Mark S.Basic and Clinical Pharmacology. 8th ed. 2001:512-531.Katzung Bertrum, ed. 2001:512-531.
12. Deecher DC,Beyer CE,Johnston G, et al.Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor.J Pharmacol Exp Ther. 2006;318 (2): 657-665.
13. Tzschentke TM,Jahnel U,Kogel B, et al.Tapentadol hydrocholoride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule.Drugs Today. 2009;45 (7): 483-496.
14. Bazhene Fidman,Nogid Anna.Role of tapentadol immediate release (Nucynta) in the management of moderate to severe pain.Pharm Therap. 2010;35 (6): 330-333.
15. Tzschentke TM,Christoph T,Kögel B, et al.(-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol hcl): a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.J Pharmacol Exp Ther. 2007;323 (1): 265-276.
16. Guay DR.Is tapentadol an advance on tramadol?.Consult Pharm. 2009;24 (11): 833-840.
17. Drug Enforcement Administration, 21CFR Part 1308. June 22, 2009.
18. Christoph T,De Vry J,Schiene K,Tallarida RJ,Tzschentke TM.Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain.Eur J Pharmacol. 2011;666 (1-3): 72-79.
19. Christoph T,De Vry J,Tzschentke TM.Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse-model of diabetic neuropathic pain.Neurosci Lett. 2010;470 (2): 91-94.